The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Real-world incidence of ibrutinib-related cardiotoxicity in CLL: insights from the LLS registry
Lee Greenberger, PhD, Leukemia & Lymphoma Society, New York, NY, shares real-world insights from the Leukemia & Lymphoma Society (LLS) patient registry on cardiotoxic events associated with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukemia (CLL). Common cardiovascular symptoms, such as atrial fibrillation and hypertension, prompted some patients to discontinue treatment with BTK inhibitors, while others managed these events with their physicians. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
